Prelox Helps To Support:
- Four Clinical Studies
- Supports Healthy Micro-Circulation and Blood Flow*
- Promotes Male Sexual Health*
- Enhances Healthy Sexual Functioning*
- Supports Maintenance of Normal, Healthy Male Fertility*
A Patented Way for Men to Rediscover Optimal Performance
Age can take its toll on some of life’s greatest pleasures. Prelox® is a
patented combination of two clinically tested ingredients that
supports sexual pleasure and performance in men. The two active ingredients are
Pycnogenol® and L-arginine aspartate, both of which have been tested
independently for safety and effectiveness towards human health. Together these
ingredients promote nitric oxide (NO) synthesis, a key mechanism for improving
sexual performance. While simple L-arginine by itself can influence male sexual
performance, burdensome doses were needed for research subjects to be able to
attain desired results.1
The Power of Pycnogenol and L-arginine Working Together
With Prelox® there appears to be a synergistic effect between
its form of L-arginine and the Pycnogenol®, affording much smaller serving sizes
per day to achieve outstanding results. The success of Prelox® in improving
spontaneous response to sexual arousal was demonstrated in not just one, but
four clinical trials—where men also experienced more confidence and frequency in
their sexual activity.2
Recent findings from clinical research bring to light even
more good news about what Prelox® has to offer: Prelox® promotes a positive
influence on the maturation of sperm and the maintenance of normal, healthy
semen parameters (measures of sperm health) in men although it has not yet been
established if this would impact or influence fertility.3
What is Pycnogenol®?
Pycnogenol® (PYC) is the trade name for a specific
standardized extract containing a concentrated blend of polyphenols derived from
the bark of French maritime pine. Traditional use of pine bark was recorded by
Hippocrates, dating its historic use to over 2000 years ago.4 More contemporary
interest in the effects of pine bark on human health evolved from the chronicles
of Jacques Cartier: his crew was saved from scurvy by consuming a decoction of
pine bark & leaves recommended by Canadian natives in 1535.
Today, Pycnogenol® is prepared from the cleaned bark of timber
trees from the pine forests of coastal southwestern France. Numerous types of
safety studies have been conducted on this ingredient, and no safety concerns
Pycnogenol® is mainly made up of procyanidins and phenolic
acids, two classes of polyphenols that are valued for their antioxidant and
other biological activity. In fact, Pycnogenol® has been studied extensively
for its influence in several areas besides sexual health. Pycnogenol® has been
noted as being able to influence cognitive function, cardiovascular health,
immune function, inflammatory response, and other aspects of our biology—in
large part due to the antioxidant strength of the polyphenols.4, 6
- Stanislavov, R., V. Nikolova, and P. Rohdewald, Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial. Int J Impot Res, 2007.
- Lamm, S., Prelox® for improvement of erectile quality. European Endocrinology, 2009. 5(1): p. 70-74.
- Stanislavov, R., V. Nikolova, and P. Rohdewald, Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother Res, 2009. 23(3): p. 297-302.
- Packer, L., G. Rimbach, and F. Virgili, Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radical Biology & Medicine, 1999. 27(5-6): p. 704-724.
- Rohdewald, P., A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. International Journal of Clinical Pharmacology and Therapeutics, 2002. 40(4): p. 158-168.
- Ryan, J., et al., An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol, 2008. 22(5): p. 553-62.